NEW! Investment Companies Centre

Alizyme (AZM)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE Small Cap

Market Cap

£21.84m

Change Today

Price Down-0.62p ()

Share Price

9.88p

Update on Board Change

RNS Number : 8212C
Alizyme PLC
05 September 2008
 






For immediate release

5 SEPTEMBER 2008




ALIZYME ANNOUNCES UPDATE ON BOARD CHANGE 


Cambridge UK, 5 September 2008: Alizyme plc (LSE: AZM) today confirms that following the announcement of Board changes as part of the Interim Results statement on 29 August 2008, David Campbell will step down from the Board as Finance Director and Company Secretary with effect from today. 

Nick Blech, currently Corporate Projects Manager, will assume the day to day responsibilities related to the Company's accounting and financial administration, reporting directly to the CEO. Nick is also appointed as Company Secretary with immediate effect.


Tim McCarthy, CEO commented"The Board would like to thank David for his contribution to Alizyme over the last seven years and we wish him every success for the future." 


For further information, please contact:


Alizyme plc 

Tim McCarthy, Chief Executive Officer


Tel: + 44 (0) 1223 896000 

Buchanan Communications

Lisa Baderoon

Rebecca Skye Dietrich

Tel: + 44 (0) 20 7466 5000 

Tel: + 44 (0) 7721 413496



Further information on Alizyme can be found on the Company's website: www.alizyme.com



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURSSESUISASESU

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).